Withdrawal of Combination Immunotherapy in Paediatric Inflammatory Bowel Disease—An International Survey of Practice

Authors :: Richard K Russell
Paul Henderson
Eytan Wine
Johan Van Limbergen
David C. Wilson
Joseph Meredith
Paediatric Gastroenterology
Amsterdam Gastroenterology Endocrinology Metabolism
APH - Digital Health
APH - Health Behaviors & Chronic Diseases
Source :: Journal of pediatric gastroenterology and nutrition, 73(1), 54-60. Lippincott Williams and Wilkins, Meredith, J, Henderson, P, Wilson, D C, Van Limbergen, J, Wine, E & Russell, R 2021, ' Withdrawal of combination immunotherapy in paediatric inflammatory bowel disease – an international survey of practice ', Journal of pediatric gastroenterology and nutrition . https://doi.org/10.1097/MPG.0000000000003098
Publication Year :: 2021
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2021.
Abstract: OBJECTIVES: To assess current practices around the use of combination immunosuppression in paediatric inflammatory bowel disease (PIBD) with a focus on the subsequent withdrawal process. METHODS: A web-based, 43-question survey. RESULTS: Surveys were completed by 70 paediatric gastroenterologists (PGs) from 27 nations across Europe, North America, Oceania and Asia from 62 centres covering approximately 15,000 PIBD patients (median of 200 patients [interquartile range (IQR) 130-300] per centre). Routine use of co-immunosuppression was significantly higher with infliximab (IFX) versus adalimumab (ADL) ([61/70, 87.1%] compared with [23/70, 32.9%]; P

Tools